Post I-131 therapy scanning in patients with thyroid carcinoma metastases: An unnecessary cost or a relevant contribution?

Clinical Nuclear Medicine

Volumn 29, Issue 12, 2004, Pages 795-798

  Souza Do Rosário, Pedro Wesley ^a,c   Barroso, Álvaro Luís ^b   Lamego Rezende, Leonardo ^b   Lanza Padrão, Eduardo ^b   Alvarenga Fagundes, Tales ^a   Cancela Penna, Gustavo ^a   Purisch, Saulo ^a  

^a Endocrinology and Metabolism Service   (Brazil)

^b Nuclear Medicine Service   (Brazil)

^c CEPCEM   (Brazil)

Author keywords

Posttherapy scan; Thyroid cancer

Indexed keywords

IODINE 131; THYROGLOBULIN;

ADULT; AGED; ARTICLE; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; SCINTILLATION CAMERA; SCINTISCANNING; THYROID CARCINOMA; THYROIDECTOMY; TUMOR RECURRENCE; WHOLE BODY SCANNER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 9344219931     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200412000-00005     Document Type: Article

References (15)

1. Mazzaferri EL. NCCN thyroid carcinoma practice guidelines. Oncology. 1999;13(suppl 11A):391-442.
2. Schlumberger M, Mancusi F, Baudin E, et al. 131-I therapy for elevated thyroglobulin levels. Thyroid. 1997;7:273-276.
3. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987;28:1888-1891.
4. Pineda J, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80:1488-1492.
5. Schlumberger MJ. Medical progress - papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.
6. Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab. 1994;78:629-634.
7. Grigsby P. Cost minimization analysis and utility of pretreatment and posttreatment total body iodine-131 scans in patients with thyroid carcinoma. Cancer. 1998;82:931-935.
8. Fatourechi V, Hay ID, Mullan BP, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid. 2000;10:573-577.
9. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 1996;37:598-605.
10. Tubiana M, Haddad E, Schlumberger M, et al. External radiotherapy in thyroid cancers. Cancer. 1985;55:2062-2071.
11. Reynolds JC. Percent 131I uptake and post-therapy 131I scans: their role in the management of thyroid cancer. Thyroid. 1997;7:281-284.
12. Brierley J, Maxon HR. Radioiodine and external radiation therapy in the treatment of thyroid cancer. In: Fagin JA, ed. Thyroid Cancer. Boston, Dordrecht, London: Kluwer Academic;1998:285-317.
13. Mazzaferri EL, Kloos R. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463.
14. Miccoli P, Antonelli A, Spinelli C, et al. Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. Arch Surg. 1998;133:89-93.
15. Tenenbaum F, Corone C, Schlumberger M, et al. Thyroglobulin measurement and postablative iodine-131 total body scan after thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease. Eur J Cancer. 1996;32A:1262.